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By contrast, bFGF expression was lower in EOC than in 
benign ovarian tumors and ovary samples. EMMPRIN 
expression in EOC was directly correlated with VEGF 
expression and CD105-MVD, but inversely correlated with 
bFGF expression. Grade 2/3 ovarian cancers had increased 
expression of EMMPRIN and VEGF, increased CD105-
MVD, and lowered expression of bFGF compared to grade 
1 ovarian cancers. Moreover, EMMPRIN expression was 
higher in advanced (FIGO III and IV) ovarian cancer.
Conclusions The upregulation of EMMPRIN and VEGF 
expression is correlated with increased CD105-MVD and 
silenced bFGF, which suggests early and/or reactivated 
angiogenesis in ovarian cancer. Aggressive EOC is char-
acterized by the following: high expression of EMMPRIN 
and VEGF, high CD105-MVD, and low expression of 
bFGF.
Keywords Extracellular matrix metalloproteinase 
inducer · EMMPRIN · Vascular endothelial growth 
factor · Basic fibroblast growth factor · Ovarian cancer · 
Angiogenesis
Introduction
Epithelial ovarian cancer (EOC) is the leading cause of 
death from gynecological malignancies and the fifth lead-
ing cause of cancer-related death among women in the 
United States (Jemal et al. 2010). The 5-year survival rate 
is approximately 45.6 % (Howlader et al. 2012). Although 
complete remission after the primary treatment is achieved 
in approximately half of patients, the majority will relapse, 
and the disease then becomes fatal (Gadducci et al. 1998; 
du Bois et al. 2003). The poor prognosis of ovarian cancer 
patients has motivated the development of new anticancer 
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therapies. Recently, antiangiogenic treatments have been 
introduced, and several trials have reported encourag-
ing results in the management of ovarian cancer patients 
(Burger 2011).
Current antiangiogenic strategies are primarily based 
on the inhibition of vascular endothelial growth fac-
tor (VEGF). Two randomized placebo-controlled trials 
reported a significant response and prolonged progression-
free survival (PFS) after the incorporation of bevacizumab, 
an anti-VEGF monoclonal antibody, into the primary 
chemotherapy regimen for ovarian cancer patients (Burger 
et al. 2011; Perren et al. 2011). However, after the discon-
tinuation of maintenance bevacizumab therapy, the disease 
was exacerbated, and no improvement in overall survival 
was observed (Burger et al. 2011; Perren et al. 2011). In the 
case of recurrent or persistent ovarian cancer, bevacizumab 
monotherapy produced a 16–21 % response rate, and the 
median PFS was less than 5 months (Burger et al. 2007; 
Cannistra et al. 2007). Taken together, these results sug-
gest that anti-VEGF therapy in ovarian cancer is effective 
but insufficient. Particularly in the primary treatment, the 
improvement in PFS was modest (Tomao et al. 2013; Col-
linson et al. 2013). The multipurpose blockade of VEGF 
and other proangiogenic factors may be more effective 
than a single anti-VEGF approach (Bergers and Hanahan 
2008; Alessi et al. 2009; Burger 2011). Potential strate-
gies include the application of multikinase inhibitors that 
impede the signaling of several important proangiogenic 
molecules, such as VEGF, platelet-derived growth factor 
(PDGF), and fibroblast growth factor (FGF). Such multi-
kinase inhibitors are currently in clinical trials in ovarian 
cancer patients (Burger 2011).
Extracellular matrix metalloproteinase inducer (EMM-
PRIN), also known as basigin or cluster of differentiation 
147 (CD147), is another candidate for the antiangiogenic 
treatment of cancer. EMMPRIN is a transmembrane pro-
tein member of the immunoglobulin family of receptors 
(Weidle et al. 2010). As a membrane protein, EMM-
PRIN has been suggested to act via cell–cell interac-
tions with surrounding cells to stimulate the secretion of 
matrix metalloproteinases (MMPs) (Biswas et al. 1995). 
Homotypic EMMPRIN–EMMPRIN interactions are 
likely responsible for EMMPRIN activity (Sun and Hem-
ler 2001; Seizer et al. 2009). However, it is not known 
whether direct cell–cell contact is necessary because 
soluble EMMPRIN and EMMPRIN-enriched tumor 
microvesicles also have the ability to stimulate the secre-
tion of MMPs (Li et al. 2001; Egawa et al. 2006; Millim-
aggi et al. 2007).
High expression of EMMPRIN has been observed in 
various human neoplasms and frequently correlated with 
cancer aggressiveness (Zucker et al. 2001; Riethdorf et al. 
2006). In cancer development, EMMPRIN stimulates the 
secretion of MMPs, which leads to the destruction of the 
extracellular matrix to facilitate cancer cell migration, 
metastasis, and angiogenesis (Gabison et al. 2005; Wei-
dle et al. 2010). Furthermore, EMMPRIN also stimulates 
VEGF secretion (Tang et al. 2005; Voigt et al. 2009; Bou-
gatef et al. 2009). It was also shown that EMMPRIN may 
enhance angiogenesis by activating the proliferation, sur-
vival, and migration of endothelial cells (ECs) (Chen et al. 
2009).
Although several studies have identified EMMPRIN 
expression in ovarian cancer, little is known about the 
role of EMMPRIN in the angiogenesis of ovarian cancer. 
Thus, the main purpose of this study was to investigate the 
potential association between the expression of EMMPRIN 
and other proangiogenic factors with microvessel density 
(MVD) in ovarian cancer samples.
Materials and methods
Participants
The study group included 58 samples of EOC collected 
from women treated in the Division of Gynecological Sur-
gery, Poznan University of Medical Sciences, Poland, dur-
ing the years 2007–2012. The control group comprised 35 
samples of benign ovarian tumors taken from patients who 
were operated on in our division. In addition, 21 samples of 
normal ovaries were obtained from perimenopausal women 
(median age 51; range 46–55 years), operated on due to 
non-oncological conditions. The materials obtained during 
surgery were divided into 2 parts. The first part was fixed in 
buffered formalin, and the second part was frozen just after 
collection and stored at −82 °C.
Tumors removed during surgery were examined his-
topathologically and classified according to WHO crite-
ria. The histological types of the EOCs included in the 
study were as follows: 22 serous, 8 mucinous, 7 endome-
trioid, 4 clear cell adenocarcinomas, and 17 undifferen-
tiated carcinomas. The group of benign ovarian tumors 
included the following: 10 serous and 5 mucinous cys-
tadenomas, 7 endometrioid cysts, 10 adult teratomas, and 
3 fibrothecomas. Malignant tumors were classified into 
three histological grades; 13, 11, and 34 tumors were 
classified as grades 1, 2, and 3, respectively. The clini-
cal stage of the disease was specified using the criteria of 
the International Federation of Gynecology and Obstet-
rics (FIGO). Malignant tumors were classified according 
to the FIGO stage of the disease as follows: 15 stage I 
patients, 9 stage II patients, 24 stage III patients, and 10 
stage IV patients.
This study received local ethics committee approval, and 
all patients signed consent forms before participating.
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EMMPRIN, VEGF, and bFGF expression
The expression of EMMPRIN, VEGF, and bFGF was 
assessed by ELISA of tissue homogenates. Homogenates 
were obtained from freshly frozen tissue samples. The ana-
lyzed tissue specimens were homogenized mechanically in 
a buffer containing 150 mM NaCl (Sigma Aldrich, USA), 
5 mM EDTA (Sigma Aldrich, USA), 50 mM Tris–HCl, 
pH 7.4 (Sigma Aldrich, USA), 1 % Triton X-100 (Sigma 
Aldrich, USA), and a protease inhibitor cocktail (Sigma 
Aldrich, USA, catalogue number S8820). The homogen-
ates were centrifuged for 15 min in Eppendorf tubes at 
10,000 rpm. The supernatants were used for ELISA to meas-
ure the concentration of proangiogenic factors (VEGF, bFGF, 
and EMMPRIN). We used commercially available ELISA 
kits obtained from R&D Systems, Minneapolis, Minnesota, 
USA. The expression of VEGF, bFGF, and EMMPRIN is 
reported as the tissue protein content (pg/mg total protein). 
Protein concentrations were assessed according to Lowry’s 
method. No repeated freeze–thaw cycles were performed 
before ELISA analysis in any case. Before analysis, we 
have performed micro-dissection to exclude connective tis-
sue and large vessels from the specimen. The samples were 
not batched for the analysis, and until statistical analysis, all 
the members of the team involved in ELISA analysis were 
blinded against studied groups. The analyses were performed 
in duplicates for each series, and following coefficients of 
variation (cv) were calculated for intra-assay variability: 
VEGF = 13 %; bFGF = 6.98 %, EMMPRIN = 11.00 %.
Immunohistochemistry and MVD assessment
Formalin-fixed tissue samples were used to evaluate MVD. 
Immunohistochemistry was used for endothelium labeling 
with antibodies against CD105, CD31, and CD34. A modi-
fied protocol proposed by Rubatt et al. (2009) was used for 
the assessment of MVD. Briefly, one observer screened the 
whole sample by light microscopy at 40× magnification to 
identify the three largest microvessel clusters (“hot spots”). 
Only hot spots located near neoplastic cells were analyzed. 
Subsequently, microvessels were counted in each of the 
selected hot spots at 400× magnification. Only microves-
sels with lumen were considered. Large vessels and vessels 
with muscular walls were not counted. The median number 
of microvessels from 3 hot spots was used for the final anal-
ysis. MVD assessment was conducted by histopathologist 
experienced in angiogenesis studies. Representative immu-
nohistochemical staining is presented in Fig. 1.
Statistical analysis
Statistical analysis was performed with GraphPad 
InStat 3.06, and following statistical tests were used: 
Kolmogorov–Smirnov test (K–S test), Kruskal–Wallis test 
(nonparametric ANOVA) with Dunn’s multiple compari-
sons test as a post hoc test, unpaired t test, Mann–Whitney 
test, and Spearman rank correlation. Logistic regression 
was conducted using MedCalc 11.4.2.0 software.
Results
VEGF, bFGF, and EMMPRIN in EOCs, benign ovarian 
tumors, and normal ovaries
The median EMMPRIN expression in the EOC group was 
significantly higher than that in the benign ovarian tumor 
and normal ovary groups (P = 0.0002). Similarly, the 
median VEGF expression was higher in the EOC group 
compared to the benign ovarian tumor and normal ovary 
groups (P < 0.0001). By contrast, the median bFGF expres-
sion was significantly lower in the EOC group compared 
to the benign ovarian tumor and normal ovary groups 
(P < 0.0001). These results are summarized in Table 1.
MVD in the studied groups
We observed significantly higher (P = 0.0003) MVD in the 
ovarian cancer tumors (25 vessels/mm2; range 0–57) than in 
the benign ovarian tumors (6 vessels/mm2; 0–70) and normal 
ovaries (6 vessels/mm2; 0–26), as assessed by CD105 staining. 
There were no differences in MVD as assessed by antibodies 
against CD31 and CD34 between the three studied groups. 
The results of the MVD assessment are presented in Table 2.
Proangiogenic factors expression in relation to MVD
In the EOC group, EMMPRIN expression positively cor-
related with MVD assessed by CD105 staining (R Spear-
man = 0.308, P = 0.031). Similarly, the expression of 
VEGF correlated positively with CD105-MVD (R Spear-
man = 0.285, P = 0.049). By contrast, there was no signifi-
cant relationship between bFGF expression and CD105-MVD 
(R Spearman = −0.149, P = 0.314). Neither CD31-MVD 
nor CD34-MVD correlated with the expression of any of the 
analyzed proangiogenic factors. The correlation results are 
summarized in Table 3. In the logistic regression model, none 
of the three analyzed proangiogenic factors was found to be 
an independent prognostic factor of CD105-MVD higher 
than the 75th percentile (>38 microvessels/mm2).
Reciprocal correlations between expression 
of proangiogenic factors
The analysis of correlations between the expression of 
proangiogenic factors revealed a significant positive 
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Fig. 1  Clear cell ovarian carcinoma showing high MVD for all of the analyzed endothelial markers: CD31 (a), CD34 (b), and CD105 (c). 
Hematoxylin and eosin staining of the tumor is presented in (d)
Table 1  Median concentration of proangiogenic factors within the three analyzed groups
Bold values are statistically significant (P < 0.05)
Ovarian cancer (n = 58) Benign ovarian tumors (n = 35) Normal ovaries (n = 21) P value
VEGF
Median pg/mg protein (range, min–max)
444.64 (0–3,000.00) 2.02 (0–634.75) 4.93 (1.67–79.35) <0.0001
EMMPRIN
Median ng/mg protein (range, min–max)
33.41 (8.48–106.50) 22.94 (13.26–48.38) 21.06 (10.65–40.75) 0.0002
bFGF
Median ng/mg protein (range, min–max)
0.97 (0.17–13.32) 2.20 (0.67–50.31) 8.04 (2.56-12.91) <0.0001
Table 2  MVD assessment in the studied group of patients and the healthy individuals
CD105-MVD, CD31-MVD, and CD34-MVD refer to MVD assessed with antibodies against CD105, CD31, and CD34, respectively
Bold value is statistically significant (P < 0.05)
Ovarian cancer (n = 58) median  
vessels/mm2 (range, min–max)
Benign ovarian tumors (n = 35) Median  
vessels/mm2 (range, min–max)
Normal ovaries (n = 21) median  
vessels/mm2 (range, min–max)
P value
CD105-MVD 25 (0–57) 6 (0–70) 6 (0–26) 0.0003
CD31-MVD 76 (19–241) 70 (6–399) 60 (31–284) 0.817
CD34-MVD 70 (6–190) 70 (6–386) 114 (31–354) 0.077
365J Cancer Res Clin Oncol (2014) 140:361–369 
1 3
correlation between EMMPRIN and VEGF expression (R 
Spearman = 0.364, P = 0.006), whereas the expression of 
EMMPRIN was inversely proportional to bFGF expres-
sion (R Spearman = −0.28, P = 0.035). The correlation 
between the expression of bFGF and VEGF was insignifi-
cant (R Spearman = −0.248, P = 0.07).
Proangiogenc factors expression and MVD 
regarding clinical features of EOC
The median EMMPRIN concentration was significantly 
higher in advanced ovarian cancer samples (FIGO III 
and IV) compared to early-stage tumor samples (FIGO I 
and II) (P = 0.013). Moreover, grade 2/3 ovarian cancers 
were characterized by the increased expression of EMM-
PRIN and VEGF, increased CD105-MVD, and the lowered 
expression of bFGF compared to grade 1 ovarian cancers 
(P = 0.026, 0.019, 0.017, and 0.018, respectively). Tables 4 
and 5 show the expression of proangiogenic factors and 
the MVD assessment according to FIGO stage and the 
grade of ovarian cancer, respectively. However, we found 
no differences in EMMPRIN expression between various 
histopathological types of ovarian cancer. Similarly, there 
were no differences in VEGF or bFGF expression or MVD 
Table 3  Correlation analyses between the expression of proangiogenic factors and MVD in the EOC group
CD105-MVD, CD31-MVD, and CD34-MVD refer to MVD assessed with antibodies against CD105, CD31, and CD34, respectively
Bold values are statistically significant (P < 0.05)
CD105-MVD (P value) CD31-MVD (P value) CD34-MVD (P value)
VEGF R Spearman = 0.285 R Spearman = 0.005 R Spearman = −0.086
P = 0.049 P = 0.973 P = 0.577
EMMPRIN R Spearman = 0.308 R Spearman = 0.193 R Spearman = 0.151
P = 0.031 P = 0.183 P = 0.323
bFGF R Spearman = −0.149 R Spearman = −0.256 R Spearman = −0.167
P = 0.314 P = 0.08 P = 0.278
Table 4  Expression of 
proangiogenic factors and MVD 
according to the FIGO stage of 
ovarian cancer
CD105-MVD, CD31-MVD, 
and CD34-MVD refer to MVD 
assessed with antibodies against 
CD105, CD31, and CD34, 
respectively
Bold value is statistically 
significant (P < 0.05)
FIGO I and II (n = 24) FIGO III and IV (n = 34) P value
VEGF
Median pg/mg protein (range, min–max)
270.35 (0–2,371.3) 610.35 (10.14–3,000.0) 0.134
EMMPRIN
Median ng/mg protein (range, min–max)
26.52 (8.48–90.28) 37.55 (10.65–106.50) 0.013
bFGF
Median ng/mg protein (range, min–max)
0.88 (0.27–13.32) 1.03 (0.17–8.33) 0.966
CD105-MVD
Median vessels/mm2 (range, min–max)
16 (0–57) 25 (0–51) 0.203
CD31-MVD
Median vessels/mm2 (range, min–max)
63 (25–203) 76 (19–241) 0.392
CD34-MVD
Median vessels/mm2 (range, min–max)
57 (6–164) 82 (32–190) 0.171
Table 5  Expression of 
proangiogenic factors and 
MVD according to the grade of 
ovarian cancer
CD105-MVD, CD31-MVD, 
and CD34-MVD refer to MVD 
assessed with antibodies against 
CD105, CD31, and CD34, 
respectively
Bold values are statistically 
significant (P < 0.05)
G1 (n = 13) G2/3 (n = 45) P value
VEGF
Median pg/mg protein (range, min–max)
257.76 (0–1265.8) 625.35 (10.14–3,000.0) 0.019
EMMPRIN
Median ng/mg protein (range, min–max)
25.92 (8.48–44.25) 35.90 (10.86–106.50) 0.026
bFGF
Median ng/mg protein (range, min–max)
2.19 (0.72–13.32) 0.82 (0.17–8.33) 0.018
CD105-MVD
Median vessels/mm2 (range, min–max)
6 (0–44) 28 (0–57) 0.017
CD31-MVD
Median vessels/mm2 (range, min–max)
63 (25–241) 76 (19–203) 0.223
CD34-MVD
Median vessels/mm2 (range, min–max)
54 (6–146) 76 (32–190) 0.153
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between the different histopathological types of ovarian 
cancer (Table 6).
Discussion
The results of our study indicate that EMMPRIN may con-
tribute to the development of new blood vessels in ovarian 
cancer. Endoglin (CD105) is a well-established marker of 
active angiogenesis, as CD105 is expressed exclusively on 
newly formed vessels (Schliemann and Neri 2007; Dallas 
et al. 2008). By contrast, CD31 and CD34 are pan-endothe-
lial markers that are found on endothelial cells of both new 
and mature vessels (Akagi et al. 2002). In the present study, 
we have shown a direct correlation between the expression 
of EMMPRIN and VEGF and MVD as assessed by anti-
bodies against CD105. Similarly, we have revealed a direct 
correlation between the expression of VEGF and EMM-
PRIN. This result is supported by the previous findings in 
other neoplasms in which EMMPRIN was shown to stim-
ulate the secretion of VEGF (Tang et al. 2005; Bougatef 
et al. 2009). However, in a logistic regression model, none 
of the analyzed proangiogenic factors independently indi-
cated increased CD105-MVD. This may suggest that both 
molecules are important during the formation of new blood 
vessels in ovarian cancer.
Although the role of VEGF in ovarian cancer angiogen-
esis is well-established, there is limited data about the role 
of EMMPRIN (Yu et al. 2013). Millimaggi et al. (Millim-
aggi et al. 2007) demonstrated that microvesicles-contain-
ing EMMPRIN shed by ovarian cancer cell lines enhanced 
the proangiogenic activities of human umbilical vein 
endothelial cells (HUVECs). The stimulation of HUVECs 
by CD147-positive microvesicles increased invasiveness, 
the proliferation rate, MMP synthesis, and the formation 
of capillary-like structures. By contrast, microvesicles of 
low EMMPRIN concentration had a diminished ability to 
induce the proangiogenic phenotype of HUVECs (Millim-
aggi et al. 2007). In another study, Millimaggi et al. (Mil-
limaggi et al. 2009) revealed that EMMPRIN expression in 
ovarian cancer cell lines is essential for vasculogenic mim-
icry (VM). VM is an alternative mechanism of angiogen-
esis in which tumor cells form tubes that act like microves-
sels. These channels are non-endothelial and are thus not 
relevant to our study, which was based on MVD evaluation 
(Millimaggi et al. 2009). VM is frequently associated with 
cancer aggressiveness (Sood et al. 2002). Indeed, in our 
study, we observed that EMMPRIN expression is higher 
in ovarian cancers diagnosed at an advanced stage and in 
grade 2/3 ovarian cancer when compared to grade 1 can-
cers. Similarly, Ueda et al. (Ueda et al. 2012) and Davidson 
et al. (2003) indicated that EMMPRIN expression was cor-
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Thus, these results may support the relationship between 
EMMPRIN, VM, and the aggressiveness of ovarian cancer.
Various preclinical studies have demonstrated the 
proangiogenic properties of basic fibroblast growth fac-
tor. This growth factor can directly stimulate the prolif-
eration and migration of endothelial cells, facilitate tube 
formation, sensitize ECs to other angiogenic factors, and 
stimulate the secretion of extracellular matrix remodeling 
proteases (Presta et al. 2005; Nissen et al. 2007). Giavazzi 
et al. (2003) suggest that bFGF and VEGF work syner-
gistically to elicit angiogenesis. Interestingly, Alessi et al. 
(2009) demonstrated that targeting bFGF may overcome 
anti-VEGF resistance; thus, anti-bFGF therapy is undergo-
ing clinical trials as an antiangiogenic therapy for ovarian 
cancer (Burger 2011). However, this is somewhat in con-
trast to our results, because we did not identify relationship 
between the expression of bFGF and the active angiogen-
esis. Therefore, we speculate that the timing of proangio-
genic factors differs in the course of angiogenesis because 
VEGF appears earlier than bFGF (Lieu et al. 2011). Thus, 
increased EMPPRIN and VEGF expressions in malignant 
tumors associated with the upregulation of CD105 suggest 
the early phase and/or very active stimulation of angiogen-
esis in the studied malignant tumors.
Our study is the first to demonstrate an inverse correla-
tion between the expression of EMMPRIN and bFGF in 
ovarian cancer tissue. Similar findings were obtained by 
Liu et al. (2011) in a study of head and neck cancer. The 
authors demonstrated that fibroblast growth factor recep-
tor 2 (FGFR2) gene expression was inversely correlated 
with EMMPRIN expression. Moreover, Liu et al. (2011) 
showed that EMMPRIN-silenced tumors had more abun-
dant stroma compared to controls. These results suggest 
that there could be an antagonistic interaction between 
EMMPRIN and bFGF. Evidence of the role of cancer-
associated fibroblasts (CAFs) in the development and 
progression of cancer is increasing (Xing et al. 2010), 
and CAFs also play a substantial role in ovarian can-
cer (Schauer et al. 2011). Liu et al. (2011) suggest that 
tumor growth is fibroblast-dependent when EMMPRIN 
expression is low, while elevated EMMPRIN expression 
promotes fibroblast-independent tumor growth. Ober-
mair et al. (1998) demonstrated that elevated tumor bFGF 
expression is correlated with favorable prognosis and that 
these tumors have greater stromal content. This is in agree-
ment with the results of our study, because we have found 
higher bFGF expression in low-grade ovarian cancers, 
which tend to have better prognosis (Malpica et al. 2004). 
Additionally, we observed lower bFGF expression in ovar-
ian cancer compared to benign ovarian tumors and nor-
mal ovaries. By contrast, some recent studies have shown 
that bFGF expression may be responsible for resistance 
to paclitaxel; thus, the exact role of bFGF as a prognostic 
factor in ovarian cancer is unclear (Gan et al. 2006). There 
appears to be close interactions between EMMPRIN and 
bFGF in the progression of ovarian cancer. However, exact 
prognostic significance of EMMRPIN/bFGF expression 
ratio should be verified according to survival analysis, and 
this is the main weakness of the presented study. We spec-
ulate that both EMMPRIN and bFGF may be key mes-
sengers between cancer cells and fibroblasts of the tumor 
stroma, but these interactions are likely very complex.
To conclude, the overexpression of EMMPRIN and 
VEGF in ovarian cancer creates a milieu of proangiogenic 
factors that may play a role in very early and/or reactivated 
angiogenesis. The upregulation of proangiogenic stimulants 
correlates with increased CD105-MVD; however, bFGF 
remains silenced. Additionally, high EMMPRIN/bFGF 
expression ratio is a new molecular profile of aggressive of 
EOC.
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